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The Twin Pillars—Knowledge and Trust 
Mark Carlson* 
Recent events have raised important questions about 
current systems for post-market surveillance and analysis of 
pacemaker and implantable cardioverter defibrillator (ICD) 
performance and the communication of that performance to 
physicians and patients.  The Policy Conference on Pacemaker 
and Implantable Cardioverter Defibrillator Performance, 
convened on September 16, 2005 by the Heart Rhythm Society 
and the United States Food and Drug Administration (FDA), 
provided an unprecedented opportunity for the major 
stakeholders—industry, the FDA, cardiac electrophysiologists, 
nurses, and patients—to discuss challenges, concerns, and 
opportunities for improvement. Several issues related to 
communication of device performance to physicians and to 
patients were addressed during the conference.  Many of these 
issues involved one of two unifying themes: knowledge and 
trust.  Physicians and patients need to receive timely, accurate, 
and understandable information regarding device performance 
in order to make appropriate decisions regarding medical care. 
Furthermore, patients need to trust that physicians, industry, 
and the FDA will always act with the best interests of patients 
in mind. 
The benefit of pacemakers and implantable defibrillators 
has been demonstrated and confirmed by countless clinical 
trials.  Thousands of lives have been saved and many more 
lives have been improved by these devices.  But like all 
manmade devices, malfunctions in pacemakers and 
implantable defibrillators can occur.  Timely detection and 
communication of malfunctions that have the potential to recur 
are critical to patient safety and necessary to improve these 
devices. 
The conference addressed postmarket surveillance, 
analysis, and reporting of device performance information to 
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FDA, physicians, and patients.  If one is to identify a device 
malfunction, one must first know the expected performance of 
the device.  It is generally understood that pacemakers and 
ICDs, which are powered by lithium batteries, have a certain 
“life expectancy” (usually a few years) due to battery depletion; 
patients do not expect their devices to function forever.  What 
may not be well-understood is that these devices, like all 
electronic devices, are subject to so-called “random component 
failure.”  Random component failure is an event that occurs 
usually due to chance and is thought to have little or no 
likelihood to occur in other devices.  The random component 
failure rate for pacemakers and ICDs is very low, but it is not 
zero. 
During the conference, patients clearly expressed that they 
desire to understand before implantation the expected 
performance and “life expectancy” of their devices, including 
the likelihood that components might fail.  Prior to 
implantation, physicians routinely counsel their patients on the 
risks and potential benefits of the procedure and the therapy 
and often discuss expected battery longevity.  Additional 
information regarding device longevity and performance could 
be provided in written form by the manufacturer and could be 
conveyed to the patient as part of the pre-procedure consent 
process. 
Postmarket surveillance is critical to timely identification 
of potential device malfunctions and precise reporting of device 
performance.  FDA uses passive surveillance (including 
mandatory and voluntary event reporting and annual reports), 
enhanced surveillance (through the Medical Product 
Surveillance Network (MedSun)), and observational studies 
(both required and discretionary) to accomplish this task. 
Passive surveillance relies on the return of devices after 
explantation or death for analysis, particularly when a 
malfunction is known or suspected.  However, industry reports 
that only a fraction of pacemakers and ICDs are returned.  
Increasing the fraction and absolute number of devices that are 
returned for analysis would enhance the surveillance process 
significantly and would have beneficial effects downstream in 
the process. 
Physicians, nurses, morticians, manufacturer 
representatives, and patients and their families play an 
important role in returning devices that provide useful 
information.  Some may be unaware of the importance of 
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returning the device even when it appears that it has 
performed very well.  Others may not be aware of what must be 
done to return a device properly.  The handling of a device after 
it is removed can affect the quality of the data available for 
analysis.  Removing an active device or cutting the leads when 
a device is active can corrupt the stored data and make it 
difficult to assess device performance. 
Educational programs may improve the rate of return and 
the quality of the information that is available for analysis.  All 
of the relevant parties should understand the importance of 
returning these devices and the process for doing so.  Those 
who remove devices (physicians and morticians) should 
understand how to do so properly in order to retain as much 
data as possible. 
Additional options to enhance surveillance include the use 
of current and new databases, new electronic remote 
monitoring capabilities, and incentives or regulatory 
requirements.  Countries with some of the highest return rates, 
like Denmark, provide financial incentives to physicians and 
patients to return devices; payment of medical bills depends on 
return of the device.  Providing similar incentives or 
requirements for return of devices in the United States would 
constitute a major change in public policy. 
The current system for surveillance and analysis of 
pacemaker and ICD performance relies to a significant extent 
on the manufacturers who receive and analyze information and 
devices from the field and report findings to the FDA, 
physicians, and patients.  Although FDA has some ability to 
discover findings independently, the system depends on the 
manufacturer acting in the best interest of all to identify and 
report significant device problems accurately and in a timely 
fashion.  As was pointed out in the policy conference, it is in the 
manufacturer’s best long-term interest to do so.  However, it 
was also noted that manufacturers could encounter 
disincentives, primarily short-term financial ones, to disclose 
such information.  For instance, it was noted that the discovery 
of a significant problem in a device with considerable unsold 
inventory could affect a manufacturer’s expected revenue 
dramatically.  Furthermore, disclosure of potential 
malfunctions is not welcome news to investors and can affect 
stock prices adversely. 
Industry has used certain practices that limit these 
potential conflicts and other practices might be considered.  
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When a potential device malfunction is identified, 
manufacturers often convene a group of physician experts to 
discuss the implications, suggest the best approach to 
mitigation, and communicate information to physicians and 
patients.  Some have suggested that an independent group of 
experts could serve industry and the FDA for all such 
circumstances.  Others have suggested that an independent 
body, such as the underwriters’ laboratory, might be best-
suited to collect, analyze, and report information on device 
performance.  However, some believe that such an approach 
would be costly, burdensome, and problematic, given, among 
other things, the proprietary information associated with many 
devices.  They believe that the manufacturer is best-positioned 
to analyze and make adjustments in devices and that only 
minor, if any, adjustments to the current system are required. 
Patients and physicians have expressed the desire for 
certainty which might be achieved by standardizing certain 
communication processes.  Several expressed the desirability of 
identifying triggers for notifying physicians and patients of a 
potential for device malfunction.  These triggers could be based 
on the objective risk level (for example, 1/1000 or 1/5000 
incidence) or the subjective risk level (such as the potential 
impact of the malfunction on the patient’s health).  One 
problem with triggers based on objective risk level is that 
people do not agree on what likelihood of event occurrence 
constitutes an acceptable risk; neither physicians nor patients 
appear to agree on the risk level at which notification should 
occur.  Furthermore, basing the trigger on objective risk alone 
does not account for the variable impact on health of different 
device malfunctions. Another approach is to base triggers for 
notification on the potential impact of the malfunction on 
patients’ health.  Such a trigger would need to account for the 
variable impact that some malfunctions may have between 
patients.  It seems clear that both the objective and subjective 
risks must be considerations in any system, and that some 
uncertainty will exist for individual patients.  In the end, 
patients may be willing to accept some uncertainty if they can 
trust that under certain circumstances they, and their 
physicians, will be notified of a potential device malfunction. 
Patients and physicians have also expressed the desire for 
standardized device performance reports. Opportunities exist 
for standardization among manufacturers of annual reports 
and notifications of device malfunction that could enhance the 
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interpretation of the information.  Reports could include 
similar information and display that information in a common 
format.  It has been recognized however, that differences in 
devices and potential malfunctions make standardized 
reporting a challenging goal. 
Furthermore, patients and physicians have expressed the 
desire to better understand the terms that are used when 
notified of a potential device malfunction.  Many patients do 
not understand medical device recall terminology, the different 
types of recalls, or the implications of these terms for medical 
care.  The term “recall” can cause unnecessary concern and 
confusion because the implications of the term when used for 
non-medical products can be significantly different than when 
the term is used for a pacemaker or implantable defibrillator. 
Moreover, it is not clear that patients thoroughly understand 
the differences in recall classification: class I for potential 
malfunctions that are life-threatening and class II for potential 
malfunctions that are not life-threatening.  Revision of the 
current terminology is no simple task because it is stipulated in 
the federal code.  In the short term, patients may benefit from 
education regarding the meaning and medical implications of 
these terms. 
Patients want to hear from their physicians when a 
potential malfunction in their device is reported.  Physicians 
would prefer that their patients heard from them first.  FDA 
and industry have traditionally communicated with patients 
through their physicians.  However, in an environment where 
information can be shared “real time” through the media and 
the Internet, and publicly traded companies are required to 
share information quickly with investors, patients often do not 
learn of a potential device malfunction from their physicians.  
This situation is not likely to change unless medical electronic 
information systems and communication systems become much 
more robust.  New remote monitoring technology might provide 
opportunities for rapid patient communication in the future.  
Until then, patients and physicians should expect that they 
may sometimes learn of device problems through sources other 
than the FDA or industry.  Nonetheless, patients should 
consult their physicians to understand the implications of any 
potential malfunction for their medical care. 
Indeed, the implications of a potential device malfunction 
may vary greatly among patients.  For instance, sudden loss of 
pacing could be life-threatening in a patient without an 
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underlying heart rhythm but completely inconsequential in a 
patient with an ICD who has no risk for a slow heart rhythm.  
The recommended actions for these two patients might be quite 
different.  Furthermore, patients need to understand the 
potential consequences (risks and benefits) of the actions that 
they might take to mitigate the risk of a potential device 
malfunction.  Replacing a pacemaker or defibrillator lead or 
pulse generator can entail risk and in some cases that risk may 
be greater than the risk associated with the potential 
malfunction.  Here too, the risk associated with device 
replacement may vary significantly between patients.  A 
patient’s physician is best qualified to understand these issues 
and provide appropriate advice. 
But the physician is not the only source of information 
from which patients wish to hear.  Patients have stated that 
they want to receive information from the manufacturer and 
from FDA.  Some patients value the opportunity to talk directly 
with their physician and the device manufacturer 
representative simultaneously.  In certain cases, some 
physicians have invited their patients to meet with them and 
an industry representative in an open forum.  Patients, 
physicians, and the industry representatives have found that 
this open dialogue enhances communication and helps to 
maintain trust. 
The Device Performance Policy Conference provided an 
opportunity for open dialogue among patients, physicians, 
industry, and government that was unprecedented.  The 
conference provided a clearer understanding of the complex 
surveillance, analysis, and communication processes and the 
opportunities for improvement.  The knowledge that was 
shared benefited all involved and provided a basis for next 
steps.  Perhaps the most crucial lesson learned during the 
conference was the importance that the FDA, device 
manufacturers, and physicians collaborate to improve the 
system.  Patients are depending on us to continue to work 
together and to place their interests first.  Only by doing so will 
patients trust their devices and those of us who are responsible 
for their medical care. 
 
